Eshepa Tablet (Tenofovir Disoproxil Hemifumarate)

Adult dose

Adults For the treatment of HIV-1 or chronic hepatitis B, take 1 tablet (equivalent to 245 mg of tenofovir disoproxil) once daily. It may be taken with or without food. The optimal duration of treatment for chronic hepatitis B is unknown. 2. Patients with renal impairment For patients with a baseline creatinine clearance of <50mL/min, adjust the dosing interval of this medicine with reference to Table 1. No adjustment to the dosing interval is needed in patients with mild renal impairment (creatinine clearance 50-80mL/min); regularly monitor calculated creatinine clearance and serum phosphate (see Warning 3). Table 1. Adjustment of dosing interval according to creatinine clearance Creatinine clearance (mL/min)a ≥50: every 24 hours 30-49: every 48 hours 10-29: every 72-96 hours Patients on hemodialysis: every 7 days or approximately 12 hours after dialysisb The pharmacokinetics of tenofovir have not been evaluated in patients with creatinine clearance below 10mL/min who are not receiving hemodialysis; therefore, no dosing recommendations are available for these patients. a. Calculated using ideal (lean) body weight. b. Generally, administer once weekly, assuming 3 hemodialysis sessions per week, each lasting approximately 4 hours. This medicine should be administered after dialysis is completed.

Child dose

Pediatric patients aged 12 years and older (35 kg or more) For the treatment of HIV-1 or chronic hepatitis B, take 1 tablet (equivalent to 245 mg of tenofovir disoproxil) once daily. It may be taken with or without food. The safety and efficacy of this medicine have not been established in pediatric patients with chronic hepatitis B who weigh less than 35 kg. There are no data to support dosage recommendations for pediatric patients with renal impairment.

This medication may cause a sudden worsening of hepatitis if treatment is discontinued; therefore, it must be taken continuously according to the physician's instructions. Patients who have allergies to any components of this medication or have certain genetic metabolic disorders should not take it. Since this medication is primarily excreted by the kidneys, patients with reduced kidney function should undergo kidney function tests before taking it and should routinely monitor their kidney status during treatment. This medication should not be taken with certain other antiviral agents, particularly those that may cause renal toxicity. If symptoms such as bone pain, fractures, or muscle weakness occur during treatment, consult healthcare professionals immediately; a bone density test may be required. It can be used during pregnancy if necessary, but a discussion with a healthcare professional is essential before use. Nursing mothers are advised to avoid breastfeeding during treatment. For pediatric patients under 12 years of age or those weighing less than 35 kg, its safety and efficacy have not been sufficiently established, so caution is advised. Elderly patients are at increased risk of impaired liver and kidney function; therefore, monitoring should be more diligent during use. In case of overdose, seek medical attention immediately for appropriate treatment; some components of this medication may be removed by hemodialysis. This medication should be stored at room temperature away from moisture or air exposure, out of reach of children, and in its original container to prevent degradation.

• Worsening of hepatitis
• acute renal failure
• Fanconi syndrome
• hypophosphatemia
• bone pain
• limb pain
• fractures
• muscle pain
• proximal tubular syndrome
• rash

This medication should be stored in a tightly sealed container to prevent exposure to air or moisture. It's best to maintain the storage temperature between 1 to 30 degrees Celsius to prolong the effectiveness of the medication.

Appearance

Light blue almond-shaped film-coated tablet

Package unit

30 tablets/bottle